Demonstrating compatibility of antibody glycosylation during biomanufacturing

EBR - European Biopharmaceutical Review

Volumn , Issue SUMMER, 2005, Pages

  Fernandes, Daryl ^a  

^a Culham Science Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; RITUXIMAB; SIALIC ACID; TRASTUZUMAB;

ACCURACY; ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG BINDING; DRUG EFFICACY; DRUG MANUFACTURE; DRUG POTENCY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOGENICITY; MASS SPECTROMETRY; NONHODGKIN LYMPHOMA; NONHUMAN; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY;

EID: 22944445190     PISSN: 1364369X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (3)

1. Jefferis R, Glycosylation of recombinant antibody therapeutics, Biotechnol Prog 21: pp11-16, 2005
2. Routier FH, Quantitation of the oligosaccharides of human serum IgG from patients with rheumatoid arthritis: a critical evaluation of different methods, J Immunol Methods 213: pp113-130, 1998
3. Shields RL et al, Lack of fucose on human IgG1 N-inked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity, J Biol Chem 277: pp26,733-27,740, 2002